Cargando…

COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?

BACKGROUND: COVID-19 is speculated to increase the likelihood of relapsing-remitting multiple sclerosis (RRMS) exacerbation. OBJECTIVE: To investigate the association between contraction of COVID-19 and incidence of acute MS attacks in RRMS patients six months post-infection. METHODS: This retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Etemadifar, Masoud, Sedaghat, Nahad, Aghababaee, Ali, Kargaran, Parisa K, Maracy, Mohammad Reza, Ganjalikhani-Hakemi, Mazdak, Rayani, Milad, Abhari, Amir Parsa, Khorvash, Reza, Salari, Mehri, Nouri, Hosein
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980521/ https://www.ncbi.nlm.nih.gov/pubmed/33799284 http://dx.doi.org/10.1016/j.msard.2021.102915

Ejemplares similares

Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine
por: Etemadifar, Masoud, et al.
Publicado: (2023)

Epidemiological and clinical features of pediatric-onset multiple sclerosis: A population-based study in Isfahan, Iran, between 1997-2020
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Association of COVID-19 with Disability Progression and Disease Exacerbation in People with Relapsing-Remitting Multiple Sclerosis: Evidence from a Year-Long Observational Study
por: Sedaghat, Nahad, et al.
Publicado: (2022)

Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Successful seroconversion following mild COVID-19 contraction in a double-vaccinated B-cell-depleted person with multiple sclerosis: A hint towards booster efficacy?
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Post-COVID-19 acute disseminated encephalomyelitis: Case report and review of the literature
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Movement Disorders Associated with COVID-19
por: Salari, Mehri, et al.
Publicado: (2021)

SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Multiple sclerosis in sarcoidosis patients: Two case reports
por: Etemadifar, Masoud, et al.
Publicado: (2022)

WITHDRAWN: Incidence and mortality of COVID-19 in Iranian multiple sclerosis patients treated with disease-modifying therapies
por: Etemadifar, M., et al.
Publicado: (2020)

miR-141 and miR-200a, Revelation of New Possible Players in Modulation of Th17/Treg Differentiation and Pathogenesis of Multiple Sclerosis
por: Naghavian, Reza, et al.
Publicado: (2015)

Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity
por: Sedaghat, Nahad, et al.
Publicado: (2023)

Myasthenia gravis and coronavirus disease 2019: A report from Iran
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Semaphorin-3A as An Immune Modulator Is Suppressed by MicroRNA-145-5p
por: Rezaeepoor, Mahsa, et al.
Publicado: (2018)

Negative Regulation of Semaphorin-3A Expression in Peripheral Blood Mononuclear Cells Using MicroRNA-497-5p
por: Shapoori, Shima, et al.
Publicado: (2019)

Upregulation of CD4+T-Cell Derived MiR-223 in The Relapsing Phase of Multiple Sclerosis Patients
por: Hosseini, Aref, et al.
Publicado: (2016)

Immunomodulatory drug fingolimod (FTY720) restricts the growth of opportunistic yeast Candida albicans in vitro and in a mouse candidiasis model
por: Najarzadegan, Niloofar, et al.
Publicado: (2022)

siRNA Delivery Improvement by Co-formulation of Different Modified Polymers in Erythroleukemic Cell Line K562
por: Ganjalikhani hakemi, Mazdak, et al.
Publicado: (2013)

MiR‐193b deregulation is associated with Parkinson's disease
por: Baghi, Masoud, et al.
Publicado: (2021)

Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma
por: Farahani, Rahim, et al.
Publicado: (2014)

Genetic defects and the role of helper T-cells in the pathogenesis of common variable immunodeficiency
por: Yazdani, Reza, et al.
Publicado: (2014)

Demographic features and clinical characteristics of patients with Parkinson’s disease in Isfahan, Iran
por: Salari, Mehri, et al.
Publicado: (2018)

Liver Resection Promotes (Regulates) Proinflammatory Cytokines in Patients with Hepatocellular Carcinoma
por: Fathi, Farshid, et al.
Publicado: (2021)

Designing and generating a single-chain fragment variable (scFv) antibody against IL2Rα (CD25): An in silico and in vitro study
por: Navabi, Parnian, et al.
Publicado: (2021)

The correlation between Flt3-ITD mutation in dendritic cells with TIM-3 expression in acute myeloid leukemia
por: Shapoorian, Hooriyeh, et al.
Publicado: (2021)

Evaluation of the T helper 17 cell specific genes and the innate lymphoid cells counts in the peripheral blood of patients with the common variable immunodeficiency
por: Ganjalikhani-Hakemi, Mazdak, et al.
Publicado: (2014)

Can COVID‐19 accelerate neurodegeneration?
por: Salari, Mehri, et al.
Publicado: (2021)

Innate lymphoid cells and cytokines of the novel subtypes of helper T cells in asthma
por: Sherkat, Roya, et al.
Publicado: (2014)

Flt3-ITD mutated acute myeloid leukemia patients and COVID-19: potential roles of autophagy and HIF-1α in leukemia progression and mortality
por: Zalpoor, Hamidreza, et al.
Publicado: (2022)

Interferon beta-1b-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) in a patient treated for multiple sclerosis: A case report
por: Etemadifar, Masoud, et al.
Publicado: (2018)

Atypical parkinsonism and self‐mutilation: A new lens on the old concept
por: Salari, Mehri, et al.
Publicado: (2021)

Atypical parkinsonism and self‐mutilation: A new lens on the old concept
por: Salari, Mehri, et al.
Publicado: (2021)

Editorial: The immunosuppressive tumor microenvironment and strategies to revert its immune regulatory milieu for cancer immunotherapy
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2023)

Complete horizontal gaze palsy due to bilateral paramedian pontine reticular formation involvement as a presentation of multiple sclerosis: a case report
por: Akhavan Sigari, Amirhossein, et al.
Publicado: (2019)

Autoimmune meningoencephalitis associated with anti‐glutamic acid decarboxylase antibody following COVID‐19 infection: A case report
por: Salari, Mehri, et al.
Publicado: (2022)

Neuromyelitis optica spectrum disorder in a patient with ankylosing spondylitis: A case report
por: Salari, Mehri, et al.
Publicado: (2023)

TIM-3 in Leukemia; Immune Response and Beyond
por: Rezaei, Mahnaz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2pa8i1uh3n27fbk16v802rp1gd